Verseon Corporation New anticoagulant data to be presented at AHA 2016
14 November 2016 - 6:00PM
RNS Non-Regulatory
TIDMVSN
Verseon Corporation
14 November 2016
Press Release November 14, 2016
Verseon Corporation
("Verseon" or the "Company")
Verseon to Present New Preclinical Safety and Tolerability
Results at the 2016 American Heart Association's Scientific
Sessions
Fremont, Calif.-Verseon will present new preclinical data on its
novel class of oral anticoagulants at the American Heart
Association's Scientific Sessions in New Orleans on November 15.
The poster will feature pharmacokinetics across several species as
well as toxicity, safety, and tolerability data that further expand
Verseon's comprehensive preclinical studies of its anticoagulant
candidates.
Using its proprietary, computer-driven discovery platform,
Verseon designs drug candidates that are unlikely to be found by
traditional drug discovery methods. The Company is advancing a
class of potent, highly selective direct thrombin inhibitors that
bind to thrombin through a unique mode of action via reversible
covalent inhibition.
In preclinical research, Verseon's direct thrombin inhibitors
show bioavailability comparable to or better than currently
available anticoagulants, suggesting that they may be suitable for
oral dosing. In addition, preclinical testing indicates that these
inhibitors carry lower bleeding risk compared to existing
anticoagulants. The Company believes that this novel class of
anticoagulants could provide new therapies for thrombotic disorders
with enhanced benefit-risk profiles.
Details of the poster, to be revealed at the American Heart
Association conference, are as follows:
Poster Title: Novel, Highly Selective Direct Thrombin
Inhibitors: Efficacy, Safety, and Tolerability Studies
Poster Number: T1204
Session Name: Thrombosis, Immunity and Inflammation
Date and Time: November 15, 2016, 12:45-2:00 PM
Location: Science and Technology Hall, Basic Science Section
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a
technology-based pharmaceutical company that employs its
proprietary, computational drug discovery platform to develop novel
therapeutics that are unlikely to be found using conventional
methods. The Company is applying its platform to a growing drug
pipeline and currently has three active drug programs in the areas
of anticoagulation, diabetic macular edema, and oncology.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Arthur Shmurun / Amy Thai 9000
Cenkos Securities (NOMAD and
Joint Broker)
+44 (0) 20
Mark Connelly / Steve Cox 7397 8900
Cantor Fitzgerald Europe (Joint
Broker)
Marc Milmo / Phil Davies / +44 (0) 20
Callum Butterfield 7894 7000
Mirabaud Securities LLP (Joint
Broker)
+44 (0) 20
Peter Krens 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd
(PR Advisers)
Henry Harrison-Topham / Sophie +44 (0) 20
Cowles 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737
Simon Vane Percy 821 890
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends, " "estimates,"
"plans," "will," "outlook," and similar expressions.
Forward-looking statements are based on management's current plans,
estimates, assumptions, and projections, and speak only as of the
date they are made. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAFFDFLKKFAF
(END) Dow Jones Newswires
November 14, 2016 02:00 ET (07:00 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024